Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche May Refine Long-Acting EPO Development Based On FDA Advisory Committee Outcome

This article was originally published in The Pink Sheet Daily

Executive Summary

An Oncologic Drugs Advisory Committee meeting on safety issues associated with Amgen's Aranesp and J&J's Procrit could affect the Phase III program for long-acting erythropoietin, Roche says.

You may also be interested in...



Aranesp, Procrit Potential Role In Tumor Proliferation Subject Of FDA Committee Review

Studies have raised questions about the angiogenic potential of erythropoietin and its role in tumor hypoxia. Oncologic Drugs Advisory Committee is not expected to address cases of pure red blood cell aplasia.

Roche Moving Two Novel Biotech Agents Into Phase III In 2004

Continuous-acting erythropoietin CERA and rheumatoid arthritis agent MRA will join ovarian cancer treatment pemtumomab to give Roche a total of three novel Phase III agents in 2004. All three biotech agents are projected for filing in next five years.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.

Topics

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel